GlassScriptPhysician profile
Mark Philip Macmillan
NPI 1285078014
$5,948.03
in general payments reported to CMS, 2019-2025
27 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what 86% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $138 · 2021: $503 · 2022: $1,127 · 2023: $1,217 · 2024: $854 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,871 · Entertainment: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,871.18 |
| Entertainment | $261.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,521.32 | 2019-2025 | Total30, Dailies Total1, Precision 1 |
| Bausch & Lomb Americas INC. | $779.89 | 2022-2025 | Infuse, Alden Scleral Zenlens, Miebo |
| Johnson & Johnson Vision Care, INC. | $736.61 | 2019-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $425.13 | 2019-2025 | Cequa |
| Optos, INC. | $261.89 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $254.87 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $226.76 | 2020-2023 | |
| Biotissue Holdings INC. | $199.22 | 2022-2024 | |
| Coopervision INC. | $171.59 | 2021-2025 | Myday Contact Lens |
| Allergan, INC. | $170.98 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $159.47 | 2019 | |
| Horizon Therapeutics Plc | $121.95 | 2022 | |
| Oyster Point Pharma, INC. | $114.26 | 2022-2025 | Tyrvaya |
| Harrow Eye, LLC | $113.29 | 2024-2025 | Vevye |
| Lkc Technologies, INC. | $109.73 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $104.52 | 2019 | |
| Maculogix, INC. | $91.54 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $80.48 | 2019 | |
| Abbvie INC. | $68.86 | 2022-2025 | |
| Carl Zeiss Meditec USA, INC. | $68.76 | 2022-2024 | Cirrus Hd-Oct |
| Carl Zeiss Meditec, INC. | $42.88 | 2019 | |
| Mallinckrodt Hospital Products INC. | $32.09 | 2023 | Acthar |
| Dompe US, INC. | $25.74 | 2025 | Oxervate |
| Thea Pharma INC. | $20.10 | 2025 | Iyuzeh |
| Amgen INC. | $17.36 | 2025 | Tepezza |
| Synergeyes, INC. | $15.66 | 2021 | |
| Abb Con-Cise Optical Group LLC | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Macmillan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.